ID   NOS2AR
AC   CVCL_RN33
DR   Wikidata; Q54930917
RX   PubMed=8097673;
RX   PubMed=8978593;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI_28748; Doxorubicin (Adriablastin; Adriamycin).
DI   NCIt; C7978; Ovarian serous cystadenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_T747 ! NOS2
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 19-12-24; Version: 5
//
RX   PubMed=8978593; DOI=10.1159/000227661;
RA   Wakahara, Yasunori
RA   Nawa, Akihiro
RA   Okamoto, Tomomitsu
RA   Hayakawa, Akemi
RA   Kikkawa, Fumitaka
RA   Suganama, Nobuhiko
RA   Wakahara, Fumiyo
RA   Tomoda, Yutaka
RT   "Combination effect of anti-Fas antibody and chemotherapeutic drugs in
RT   ovarian cancer cells in vitro.";
RL   Oncology 54:48-54(1997).
//
RX   PubMed=8097673;
RA   Maeda, Osamu
RA   Terasawa, Motomu
RA   Ishikawa, Tomohiko
RA   Oguchi, Hidenori
RA   Mizuno, Kimio
RA   Kawai, Michiyasu
RA   Kikkawa, Fumitaka
RA   Tomoda, Yutaka
RA   Hidaka, Hiroyoshi
RT   "A newly synthesized bifunctional inhibitor, W-77, enhances adriamycin
RT   activity against human ovarian carcinoma cells.";
RL   Cancer Res. 53:2051-2056(1993).
//